RELATED STUDY
Cannabidiol in inflammatory bowel diseases: a brief overview.
Key Findings: For years, its activity has been enigmatic for gastroenterologists and pharmacologists, but now it is evident that this compound may interact at extra-cannabinoid system receptor sites, such as peroxisome proliferator-activated receptor-gamma. This strategic interaction makes CBD as a potential candidate for the development of a new class of anti-IBD drugs.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Italy
Year of Pub: 2013
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Receptors Studied: PPARs
Citation: Esposito G, et al. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytother Res. 2013; 27:633-6. doi: 10.1002/ptr.4781
Authors: Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, Scuderi C, Steardo A, Cuomo R, Steardo L
